SEARCH

Current Edition

cancer

Regeneron buys control of cancer drug Libtayo from Sanofi

Dive Brief: Regeneron will pay partner Sanofi $900 million to gain global rights to the companies’ cancer immunotherapy Libtayo, announcing Thursday a deal executives said would …

Continue Reading →
biotechnology

Regeneron, in search of an eye gene therapy, turns to a young biotech

Dive Brief: Through a deal announced Wednesday, a German-based biotechnology company has agreed to help Regeneron develop a gene therapy for an inherited retinal disease. …

Continue Reading →
Antibody

Regeneron warns its antibody drug may be less potent versus omicron

Regeneron’s drug is the top-selling COVID-19 treatment in the U.S., one of three antibody drugs currently authorized by the Food and Drug Administration for people …

Continue Reading →
Antibody

US stocks up on COVID-19 antibody drugs amid shortage concerns

The antibody treatments from Regeneron and Eli Lilly have been proven effective in reducing the risk of hospitalization or death from COVID-19 in certain high-risk …

Continue Reading →
eye drug

New data bolster Regeneron’s plan to defend top-selling eye drug

While drugs like Eylea can be life-changing for patients facing the prospect of vision loss, injections in the eye are unpleasant and the possibility of …

Continue Reading →
Bristol Myers Squibb

Regeneron drug extends survival in lung cancer trial, lifting company’s hopes in field

Since its first approval in first-line lung cancer in 2016, Keytruda has proved a tough competitor for rival drugmakers to challenge with their own therapies. …

Continue Reading →